MVA-BN® is based on a novel monoclonal MVA virus strain
Our MVA-BN® patent
Vaccine vectors and MVA
MVA-BN® is Bavarian Nordic’s proprietary and patented technology. Since 1999, the company has shown MVA-BN® to be one of the safest multivalent vaccine vectors for the development of vaccines against infectious diseases and cancer.
MVA-BN® is used in most of the group’s development programmes against smallpox, HIV, cancer and other vaccines.
MVA-BN®’s potential reaches well-beyond the company’s current focus.
